Mar 24 / admin


ongoing …………Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level.

Veitonmäki T, Tammela TL, Auvinen A, Murtola TJ (2012) Eur J Cancer. ( ), .

Non-steroidal Anti-inflammatory Drugs and Endometrial Cancer Risk in the VITamins And Lifestyle (VITAL) Cohort.

Brasky TM, Moysich KB, Cohn DE, White E (2012) Gynecol Oncol. ( ), .
Aspirin in prevention of sporadic colorectal cancer: current clinical evidence and overall balance of risks and benefits.

Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials.

Algra AM, Rothwell PM (2012) Lancet Oncol. 13 (5), 518-27.

Rothwell PM (2012) Recent Results Cancer Res. 191 ( ), 121-42.

In addition to longstanding evidence from observational studies, evidence from randomised trials of the effectiveness of aspirin for chemoprevention of colorectal cancer has increased substantially in recent years. Trials have shown that daily aspirin reduces the risk of any recurrent colorectal adenoma by 17 % and advanced adenoma by 28 %, and that daily aspirin for about 5 years reduces incidence and mortality due to colorectal cancer by 30-40 % after 20 years of follow-up, and reduces the 20-year risk of all-cause cancer mortality by about 20 %. Recent evidence also shows that the risk of major bleeding on aspirin diminishes with prolonged use, suggesting that the balance of risk and benefit favours the use of daily aspirin in primary prevention of colorectal and other cancers. Updated clinical guidelines are currently awaited.

Highlight It Medicine blogs & blog posts Medicine blogs & blog posts Blog Directory Blog Directory Health blogs Health